References
1. Wan E Y F, Mathur S, Zhang R, et al. Association of COVID-19 with
short- and long-term risk of cardiovascular disease and mortality: a
prospective cohort in UK Biobank[J]. Cardiovasc Res 2023.
2. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal
Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)[J].
JAMA Cardiol 2020, 5(7): 811-818.
3. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
Wuhan, China[J]. Jama 2020, 323(11): 1061-1069.
4.Moss A J, Zareba W, Hall W J, et al. Prophylactic implantation of a
defibrillator in patients with myocardial infarction and reduced
ejection fraction[J]. N Engl J Med 2002, 346(12): 877-83.
5. Biton Y, Rosero S, Moss A, et al. Long-Term Survival With Implantable
Cardioverter-Defibrillator in Different Symptomatic Functional Classes
of Heart Failure[J]. Am J Cardiol 2018, 121(5): 615-620.
6. Moss A J. What we have learned from the family of multicenter
automatic defibrillator implantation trials[J]. Circ J 2010, 74(6):
1038-41.
7. Zabel M, Willems R, Lubinski A, et al. Clinical effectiveness of
primary prevention implantable cardioverter-defibrillators: results of
the EU-CERT-ICD controlled multicentre cohort study[J]. Eur Heart J
2020, 41(36): 3437-3447.
8. Poole J E, Olshansky B, Mark D B, et al. Long-Term Outcomes of
Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT[J]. J
Am Coll Cardiol 2020, 76(4): 405-415.
9. Strickberger S A, Canby R, Cooper J, et al. Association of
Antitachycardia Pacing or Shocks With Survival in 69,000 Patients With
an Implantable Defibrillator[J]. J Cardiovasc Electrophysiol 2017,
28(4): 416-422.
10. Wilkoff B L, Williamson B D, Stern R S, et al. Strategic programming
of detection and therapy parameters in implantable
cardioverter-defibrillators reduces shocks in primary prevention
patients: results from the PREPARE (Primary Prevention Parameters
Evaluation) study[J]. J Am Coll Cardiol 2008, 52(7): 541-50.
11. Merchant F M, Hoskins M H, Benser M E, et al. Time Course of
Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator
Discharge and Implications for Driving Restrictions[J]. JAMA Cardiol
2016, 1(2): 181-8.
12. Adabag S, Zimmerman P, Black A, et al. Implantable
Cardioverter-Defibrillator Shocks During COVID-19 Outbreak[J]. J Am
Heart Assoc 2021, 10(11): e019708.
13. Zeppenfeld K, Tfelt-Hansen J, De Riva M, et al. 2022 ESC Guidelines
for the management of patients with ventricular arrhythmias and the
prevention of sudden cardiac death[J]. Eur Heart J 2022, 43(40):
3997-4126.
14. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With
Mortality in Hospitalized Patients With COVID-19 in Wuhan, China[J].
JAMA Cardiol 2020, 5(7): 802-810.
15. Corrigendum to Coronavirus fulminant myocarditis saved with
glucocorticoid and human immunoglobulin[J]. Eur Heart J 2021, 42(2):
191.
16. Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China[J]. Lancet 2020,
395(10223): 497-506.
17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study[J]. Lancet 2020, 395(10229): 1054-1062.
18. Henning R J. Cardiovascular complications of COVID-19 severe acute
respiratory syndrome[J]. Am J Cardiovasc Dis 2022, 12(4): 170-191.
19. Inciardi R M, Lupi L, Zaccone G, et al. Cardiac Involvement in a
Patient With Coronavirus Disease 2019 (COVID-19)[J]. JAMA Cardiol
2020, 5(7): 819-824.
20.Azevedo R B, Botelho B G, Hollanda J V G, et al. Covid-19 and the
cardiovascular system: a comprehensive review[J]. J Hum Hypertens
2021, 35(1): 4-11.
21. Li S S, Cheng C W, Fu C L, et al. Left ventricular performance in
patients with severe acute respiratory syndrome: a 30-day
echocardiographic follow-up study[J]. Circulation 2003, 108(15):
1798-803.
22. Wrapp D, Wang N, Corbett K S, et al. Cryo-EM structure of the
2019-nCoV spike in the prefusion conformation[J]. Science 2020,
367(6483): 1260-1263.
23. Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on
the receptor ACE2 expression reveals the potential risk of different
human organs vulnerable to 2019-nCoV infection[J]. Front Med 2020,
14(2): 185-192.
24.Landstrom A P, Dobrev D, Wehrens X H T. Calcium Signaling and Cardiac
Arrhythmias[J]. Circ Res 2017, 120(12): 1969-1993.
25.Zorzi A, Mattesi G, Frigo A C, et al. Impact of coronavirus disease
19 outbreak on arrhythmic events and mortality among implantable
cardioverter defibrillator patients followed up by remote monitoring: a
single center study from the Veneto region of Italy[J]. J Cardiovasc
Med (Hagerstown) 2022, 23(8): 546-550.
26.Malanchini G, Ferrari P, Leidi C, et al. Ventricular arrhythmias
among patients with implantable cardioverter-defibrillator during the
COVID-19 pandemic[J]. J Arrhythm 2021, 37(2): 407-413.
27. Kochi A N, Tagliari A P, Forleo G B, et al. Cardiac and arrhythmic
complications in patients with COVID-19[J]. J Cardiovasc
Electrophysiol 2020, 31(5): 1003-1008.
28. Brigadeau F, Kouakam C, Klug D, et al. Clinical predictors and
prognostic significance of electrical storm in patients with implantable
cardioverter defibrillators[J]. Eur Heart J 2006, 27(6): 700-7.
29. Proietti R, Sagone A. Electrical storm: Incidence, Prognosis and
Therapy[J]. Indian Pacing Electrophysiol J 2011, 11(2): 34–42.
30.Oudit G Y, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of
myocardial ACE2 expression and inflammation in patients with
SARS[J]. Eur J Clin Invest 2009, 39(7): 618-25.
31. Kistamás K, Veress R, Horváth B, et al. Calcium Handling Defects and
Cardiac Arrhythmia Syndromes[J]. Front Pharmacol 2020, 11: 72.
32. Reiter M J. Effects of mechano-electrical feedback: potential
arrhythmogenic influence in patients with congestive heart
failure[J]. Cardiovasc Res 1996, 32(1): 44-51.
33. Nedios S, Darma A, Stevanello C, et al. Electrical storm in patients
with implantable cardioverter-defibrillator in the era of catheter
ablation: Implications for better rhythm control[J]. Heart Rhythm
2015, 12(12): 2419-25.
34. Van Rees J B, Borleffs C J, De Bie M K, et al. Inappropriate
implantable cardioverter-defibrillator shocks: incidence, predictors,
and impact on mortality[J]. J Am Coll Cardiol 2011, 57(5): 556-62.
35. Borleffs C J, Van Rees J B, Van Welsenes G H, et al. Prognostic
importance of atrial fibrillation in implantable
cardioverter-defibrillator patients[J]. J Am Coll Cardiol 2010,
55(9): 879-85.
36. Seecheran R, Narayan Singh R, Giddings S, et al. Atrial Arrhythmias
in a Patient Presenting With Coronavirus Disease-2019 (COVID-19)
Infection[J]. J Investig Med High Impact Case Rep 2020, 8:
2324709620925571.
37. Guzik T J, Mohiddin S A, Dimarco A, et al. COVID-19 and the
cardiovascular system: Implications for risk assessment, diagnosis, and
treatment options[J]. Cardiovasc Res 2020, 116(10): 1666-1687.